Loading…

Heparan Sulfate Modulates Kinin Release by Trypanosoma cruzi through the Activity of Cruzipain

Trypanosoma cruzi activates the kinin pathway through the activity of its major cysteine proteinase, cruzipain. Because kininogen molecules may be displayed on cell surfaces by binding to glycosaminoglycans, we examined whether the ability of cruzipain to release kinins from high molecular weight ki...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of biological chemistry 2002-02, Vol.277 (8), p.5875-5881
Main Authors: Lima, Ana Paula C.A., Almeida, Paulo C., Tersariol, Ivarne L.S., Schmitz, Veronica, Schmaier, Alvin H., Juliano, Luiz, Hirata, Isaura Y., Müller-Esterl, Werner, Chagas, Jair R., Scharfstein, Julio
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Trypanosoma cruzi activates the kinin pathway through the activity of its major cysteine proteinase, cruzipain. Because kininogen molecules may be displayed on cell surfaces by binding to glycosaminoglycans, we examined whether the ability of cruzipain to release kinins from high molecular weight kininogen (HK) is modulated by heparan sulfate (HS). Kinetic assays show that HS reduces the cysteine proteinase inhibitory activity (Kiapp) of HK about 10-fold. Conversely, the catalytic efficiency of cruzipain on kinin-related synthetic fluorogenic substrates is enhanced up to 6-fold in the presence of HS. Analysis of the HK breakdown products generated by cruzipain indicated that HS changes the pattern of HK cleavage products. Direct measurements of bradykinin demonstrated an up to 35-fold increase in cruzipain-mediated kinin liberation in the presence of HS. Similarly, kinin release by living trypomastigotes increased up to 10-fold in the presence of HS. These studies suggest that the efficiency of T. cruzi to initiate kinin release is potently enhanced by the mutual interactions between cruzipain, HK, and heparan sulfate proteoglycans.
ISSN:0021-9258
1083-351X
DOI:10.1074/jbc.M108518200